156 related articles for article (PubMed ID: 31288739)
41. Using Survival Analysis to Improve Estimates of Life Year Gains in Policy Evaluations.
Meacock R; Sutton M; Kristensen SR; Harrison M
Med Decis Making; 2017 May; 37(4):415-426. PubMed ID: 27311650
[TBL] [Abstract][Full Text] [Related]
42. Long-Term Survival Following Traumatic Brain Injury: A Population-Based Parametric Survival Analysis.
Fuller GW; Ransom J; Mandrekar J; Brown AW
Neuroepidemiology; 2016; 47(1):1-10. PubMed ID: 27165161
[TBL] [Abstract][Full Text] [Related]
43. Contributions of diseases and injuries to widening life expectancy inequalities in England from 2001 to 2016: a population-based analysis of vital registration data.
Bennett JE; Pearson-Stuttard J; Kontis V; Capewell S; Wolfe I; Ezzati M
Lancet Public Health; 2018 Dec; 3(12):e586-e597. PubMed ID: 30473483
[TBL] [Abstract][Full Text] [Related]
44. Population-based estimates of healthy working life expectancy in England at age 50 years: analysis of data from the English Longitudinal Study of Ageing.
Parker M; Bucknall M; Jagger C; Wilkie R
Lancet Public Health; 2020 Jul; 5(7):e395-e403. PubMed ID: 32619541
[TBL] [Abstract][Full Text] [Related]
45. Comparison of methods for calculating relative survival in population-based studies.
Rutherford MJ; Dickman PW; Lambert PC
Cancer Epidemiol; 2012 Feb; 36(1):16-21. PubMed ID: 21840284
[TBL] [Abstract][Full Text] [Related]
46. The global impact of noncommunicable diseases: estimates and projections.
Manton KG
World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
[TBL] [Abstract][Full Text] [Related]
47. Estimating increment-decrement life tables with multiple covariates from panel data: the case of active life expectancy.
Land KC; Guralnik JM; Blazer DG
Demography; 1994 May; 31(2):297-319. PubMed ID: 7926190
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
[TBL] [Abstract][Full Text] [Related]
49. Bayesian sensitivity models for missing covariates in the analysis of survival data.
Hemming K; Hutton JL
J Eval Clin Pract; 2012 Apr; 18(2):238-46. PubMed ID: 21114712
[TBL] [Abstract][Full Text] [Related]
50. Comparison of expected health impacts for major cancers: integration of incidence rate and loss of quality-adjusted life expectancy.
Hung MC; Lai WW; Chen HH; Su WC; Wang JD
Cancer Epidemiol; 2015 Feb; 39(1):126-32. PubMed ID: 25553846
[TBL] [Abstract][Full Text] [Related]
51. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
52. Loss in life expectancy and gain in life years as measures of cancer impact.
Rutherford MJ; Andersson TM; Björkholm M; Lambert PC
Cancer Epidemiol; 2019 Jun; 60():168-173. PubMed ID: 31054465
[TBL] [Abstract][Full Text] [Related]
53. Life expectancy as a summary of mortality in a population: statistical considerations and suitability for use by health authorities.
Silcocks PB; Jenner DA; Reza R
J Epidemiol Community Health; 2001 Jan; 55(1):38-43. PubMed ID: 11112949
[TBL] [Abstract][Full Text] [Related]
54. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life.
Bower H; Andersson TM; Björkholm M; Dickman PW; Lambert PC; Derolf ÅR
Blood Cancer J; 2016 Feb; 6(2):e390. PubMed ID: 26849011
[TBL] [Abstract][Full Text] [Related]
55. Increase in the Life Expectancy of Patients with Cancer in the United States.
Devasia TP; Howlader N; Dewar RA; Stevens JL; Mittu K; Mariotto AB
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):196-205. PubMed ID: 38015774
[TBL] [Abstract][Full Text] [Related]
56. Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts.
Dignam JJ; Huang L; Ries L; Reichman M; Mariotto A; Feuer E
Cancer; 2009 Nov; 115(22):5272-83. PubMed ID: 19670456
[TBL] [Abstract][Full Text] [Related]
57. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up.
Lee HY; Hwang JS; Jeng JS; Wang JD
Stroke; 2010 Apr; 41(4):739-44. PubMed ID: 20150543
[TBL] [Abstract][Full Text] [Related]
58. Life expectancy in pancreatic neuroendocrine cancer.
Brooks JC; Shavelle RM; Vavra-Musser KN
Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):88-97. PubMed ID: 30220478
[TBL] [Abstract][Full Text] [Related]
59. Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Med Decis Making; 2022 Oct; 42(7):945-955. PubMed ID: 35769004
[TBL] [Abstract][Full Text] [Related]
60. Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and methods.
Engholm G; Gislum M; Bray F; Hakulinen T
Acta Oncol; 2010 Jun; 49(5):545-60. PubMed ID: 20491523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
